Publicaciones en colaboración con investigadores/as de Commonwealth Scientific and Industrial Research Organisation (4)

2023

  1. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  2. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    The Lancet, Vol. 402, Núm. 10417, pp. 2077-2090

  3. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    The Lancet, Vol. 401, Núm. 10388, pp. 1584-1594

2022

  1. Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression

    Journal of the American Society of Nephrology : JASN, Vol. 33, Núm. 2, pp. 291-303